Moderna - MRNA Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $126.49
Forecasted Upside: 19.12%
Number of Analysts: 16
Breakdown:
2 Sell Ratings
8 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$106.18 As of 04/25/2024 01:00 AM ET

▼ -2.67 (-2.45%)

1 month | 3 months | 12 months

Get New Moderna Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRNA

^$126.49

▲ +19.12% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $126.49, with a high forecast of $231.00 and a low forecast of $60.00. The average price target represents a 19.12% upside from the last price of $106.18.

Current Consensus is Hold

The current consensus among 16 investment analysts is to hold stock in Moderna. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

11/2/2022

0 strong buy ratings
6 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

1/31/2023

0 strong buy ratings
6 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

5/1/2023

0 strong buy ratings
6 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

7/30/2023

0 strong buy ratings
6 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

10/28/2023

0 strong buy ratings
6 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

1/26/2024

0 strong buy ratings
6 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

3/26/2024

0 strong buy ratings
6 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

4/25/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/11/2024	Needham & Company LLC	Reiterated Rating	Hold		Low
4/9/2024	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$125.00	Low
4/1/2024	William Blair	Reiterated Rating	Market Perform		Low
3/28/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$125.00	N/A
3/28/2024	Needham & Company LLC	Reiterated Rating	Hold		Low
2/26/2024	HSBC	Reiterated Rating	Hold ➝ Reduce	$75.00 ➝ $86.00	Low
2/23/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$125.00	Low
2/23/2024	Canaccord Genuity Group	Boost Target	Hold ➝ Hold	$82.00 ➝ $91.00	Low
1/12/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$125.00	Low
1/2/2024	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$142.00	Low
12/1/2023	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	$93.00 ➝ $90.00	Low
11/29/2023	Canaccord Genuity Group	Initiated Coverage	Hold	$82.00	Low
11/29/2023	Canaccord Genuity Group	Initiated Coverage	Hold	$82.00	Low
11/3/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$180.00 ➝ $125.00	Low
11/3/2023	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$269.00 ➝ $231.00	Low
11/3/2023	HSBC	Upgrade	Reduce ➝ Hold	$89.00 ➝ $69.00	Low
11/2/2023	Deutsche Bank Aktiengesellschaft	Downgrade	Hold ➝ Sell	$125.00 ➝ $60.00	Low
9/13/2023	Argus	Lower Target	Buy ➝ Buy	$160.00 ➝ $140.00	Low
8/4/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$128.00 ➝ $123.00	Low
8/4/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$200.00 ➝ $190.00	Low
8/4/2023	Jefferies Financial Group	Lower Target		$275.00 ➝ $175.00	Low
8/4/2023	Bank of America	Lower Target	Neutral ➝ Neutral	$175.00 ➝ $150.00	Low
8/4/2023	TD Cowen	Downgrade	Outperform ➝ Market Perform	$145.00 ➝ $125.00	Low
8/3/2023	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$200.00 ➝ $125.00	Low
7/24/2023	TD Cowen	Lower Target	Outperform	$175.00 ➝ $165.00	Low
7/24/2023	William Blair	Initiated Coverage	Market Perform	$136.28	Low
7/14/2023	HSBC	Initiated Coverage	Reduce	$97.00	Low
6/26/2023	51job	Reiterated Rating	Upgrade		Low
6/26/2023	UBS Group	Upgrade	Neutral ➝ Buy	$221.00 ➝ $191.00	Low
5/5/2023	Morgan Stanley	Lower Target		$185.00 ➝ $153.00	Low
4/25/2023	Guggenheim	Initiated Coverage	Neutral		Low
4/10/2023	JPMorgan Chase & Co.	Boost Target	Neutral	$127.00 ➝ $145.00	Low
3/13/2023	TD Cowen	Upgrade	Market Perform ➝ Outperform	$150.00 ➝ $180.00	Low
3/1/2023	Royal Bank of Canada	Initiated Coverage	Outperform	$200.00	Low
2/28/2023	Deutsche Bank Aktiengesellschaft	Lower Target	Buy	$225.00 ➝ $200.00	Low
2/24/2023	SVB Leerink	Downgrade	Market Perform ➝ Underperform	$111.00 ➝ $93.00	Low
2/24/2023	SVB Securities	Downgrade	Market Perform ➝ Underperform	$111.00 ➝ $93.00	Low
2/23/2023	Morgan Stanley	Lower Target		$205.00 ➝ $185.00	Low
2/8/2023	JPMorgan Chase & Co.	Boost Target	Neutral	$132.00 ➝ $138.00	Low
1/25/2023	Cowen	Boost Target	Market Perform	$130.00 ➝ $150.00	Low
1/24/2023	Morgan Stanley	Lower Target	Equal Weight	$209.00 ➝ $205.00	Low
1/18/2023	SVB Leerink	Boost Target	Market Perform	$102.00 ➝ $111.00	Low
1/18/2023	Chardan Capital	Boost Target	Neutral	$191.00 ➝ $208.00	Low
1/11/2023	Deutsche Bank Aktiengesellschaft	Boost Target		$185.00 ➝ $225.00	Low
12/20/2022	Piper Sandler	Boost Target	Overweight	$214.00 ➝ $217.00	Low
12/19/2022	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$170.00 ➝ $275.00	Low
12/16/2022	Morgan Stanley	Boost Target	Equal Weight	$170.00 ➝ $209.00	Low
12/14/2022	Chardan Capital	Downgrade	Buy ➝ Neutral	$186.00 ➝ $191.00	Low
12/13/2022	SVB Leerink	Boost Target	Market Perform	$101.00 ➝ $102.00	Low
11/15/2022	Bank of America	Boost Target		$160.00 ➝ $182.00	Low
11/7/2022	Chardan Capital	Lower Target	Buy	$188.00 ➝ $186.00	Low
11/4/2022	Morgan Stanley	Lower Target	Equal Weight	$175.00 ➝ $170.00	Low
10/24/2022	JPMorgan Chase & Co.	Lower Target	Neutral	$165.00 ➝ $122.00	Low
10/21/2022	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$174.00 ➝ $101.00	Low
10/20/2022	Cowen	Lower Target		$165.00 ➝ $145.00	Low
10/20/2022	Cowen	Lower Target		$165.00 ➝ $145.00	Low
10/18/2022	Morgan Stanley	Lower Target	Equal Weight	$197.00 ➝ $175.00	Low
10/13/2022	The Goldman Sachs Group	Boost Target	Buy	$290.00 ➝ $296.00	Low
9/14/2022	Argus	Lower Target	Buy	$180.00 ➝ $150.00	Low
9/7/2022	Deutsche Bank Aktiengesellschaft	Upgrade	Hold ➝ Buy	$155.00 ➝ $165.00	Low
8/4/2022	Morgan Stanley	Lower Target	Equal Weight	$199.00 ➝ $197.00	N/A
8/1/2022	SVB Leerink	Boost Target	Underperform	$70.00 ➝ $77.00	Low
6/7/2022	SVB Leerink	Lower Target	Underperform	$80.00 ➝ $70.00	Low
5/17/2022	Piper Sandler	Lower Target	Overweight	$348.00 ➝ $214.00	Medium
4/12/2022	Morgan Stanley	Boost Target	Equal Weight	$205.00 ➝ $217.00	Low
3/25/2022	SVB Leerink	Lower Target	Underperform	$81.00 ➝ $80.00	High
3/7/2022	Deutsche Bank Aktiengesellschaft	Lower Target	Hold	$175.00 ➝ $155.00	High
2/28/2022	Morgan Stanley	Lower Target	Equal Weight	$213.00 ➝ $205.00	High
2/25/2022	Jefferies Financial Group	Lower Target		$200.00 ➝ $170.00	Low
2/25/2022	Barclays	Lower Target		$404.00 ➝ $210.00	Low
2/25/2022	SVB Leerink	Lower Target	Underperform	$85.00 ➝ $81.00	Medium
2/1/2022	Morgan Stanley	Lower Target	Equal Weight	$315.00 ➝ $213.00	Low
2/1/2022	Redburn Partners	Upgrade	Sell ➝ Neutral		Low
1/28/2022	SVB Leerink	Lower Target	Underperform	$86.00 ➝ $85.00	High
1/26/2022	Deutsche Bank Aktiengesellschaft	Upgrade	Sell ➝ Hold	$175.00	High
1/21/2022	UBS Group	Initiated Coverage	Neutral	$221.00	High
1/21/2022	Bank of America	Upgrade	Underperform ➝ Neutral	$135.00 ➝ $180.00	High
1/18/2022	Morgan Stanley	Boost Target	Equal Weight	$313.00 ➝ $315.00	High
1/6/2022	Argus	Lower Target		$420.00 ➝ $350.00	Low
12/23/2021	SVB Leerink	Reiterated Rating	Sell		Low
12/6/2021	Cowen	Initiated Coverage	Market Perform	$250.00	High
11/8/2021	Wolfe Research	Initiated Coverage	Outperform	$304.00	Medium
11/5/2021	SVB Leerink	Boost Target	Underperform	$85.00 ➝ $86.00	High
11/5/2021	Morgan Stanley	Lower Target	Equal Weight	$337.00 ➝ $313.00	High
11/5/2021	Jefferies Financial Group	Lower Target	Hold	$375.00 ➝ $325.00	High
11/5/2021	The Goldman Sachs Group	Reiterated Rating	Buy	$395.00	High
11/5/2021	Piper Sandler	Lower Target	Overweight	$348.00	High
10/22/2021	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Sell	$250.00	Medium
10/15/2021	Piper Sandler	Upgrade	Neutral ➝ Overweight		High
9/12/2021	SVB Leerink	Reiterated Rating	Sell		High
9/7/2021	Morgan Stanley	Boost Target	Equal Weight	$190.00 ➝ $337.00	Medium
8/6/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral		Low
8/5/2021	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Medium
7/15/2021	Jefferies Financial Group	Boost Target	Positive ➝ Hold	$170.00 ➝ $250.00	High
7/7/2021	Chardan Capital	Reiterated Rating	Buy		High
6/24/2021	Argus	Boost Target	Buy	$200.00 ➝ $230.00	Medium
5/7/2021	Chardan Capital	Boost Target	Buy	$182.00 ➝ $188.00	Low
5/7/2021	Morgan Stanley	Lower Target	Equal Weight	$201.00 ➝ $190.00	Low
5/7/2021	Barclays	Boost Target	Overweight	$178.00 ➝ $194.00	Low
5/7/2021	The Goldman Sachs Group	Boost Target	Buy	$206.00 ➝ $228.00	Low
5/6/2021	Piper Sandler	Lower Target	Overweight	$234.00 ➝ $231.00	Low
5/5/2021	Jefferies Financial Group	Reiterated Rating	Hold		High
4/21/2021	Piper Sandler	Reiterated Rating	Overweight	$208.00 ➝ $234.00	High
4/18/2021	SVB Leerink	Reiterated Rating	Sell		High
4/16/2021	Needham & Company LLC	Reiterated Rating	Hold		High
4/15/2021	Piper Sandler	Boost Target	Overweight	$208.00 ➝ $234.00	Medium
3/15/2021	Piper Sandler	Reiterated Rating	Overweight	$208.00	Medium
3/1/2021	Chardan Capital	Boost Target	Positive ➝ Buy	$107.00 ➝ $182.00	Low
2/26/2021	Barclays	Boost Target		$169.00 ➝ $178.00	Low
2/26/2021	Brookline Capital Management	Boost Target	Buy	$180.00 ➝ $205.00	Low
2/26/2021	Bank of America	Reiterated Rating	Sell	$140.00	High
2/25/2021	Morgan Stanley	Lower Target	Equal Weight	$215.00 ➝ $201.00	High
2/18/2021	Jefferies Financial Group	Boost Target		$150.00 ➝ $180.00	Medium
2/18/2021	Morgan Stanley	Boost Target	Equal Weight	$150.00 ➝ $215.00	High
2/17/2021	Piper Sandler	Boost Target		$170.00 ➝ $208.00	Low
2/1/2021	Oppenheimer	Boost Target	Outperform	$178.00 ➝ $206.00	Low
2/1/2021	Wells Fargo & Company	Boost Target	Overweight ➝ Equal Weight	$129.00 ➝ $145.00	Low
2/1/2021	SVB Leerink	Boost Target	Underperform	$69.00 ➝ $80.00	Low
2/1/2021	Bank of America	Downgrade	Neutral ➝ Underperform	$150.00	Low
1/22/2021	Bank of America	Boost Target	Neutral	$130.00 ➝ $140.00	Low
1/6/2021	Piper Sandler	Reiterated Rating	Overweight	$166.00 ➝ $170.00	N/A
12/21/2020	SVB Leerink	Boost Target	Positive ➝ Underperform	$60.00 ➝ $69.00	High
12/21/2020	Oppenheimer	Boost Target	Outperform	$157.00 ➝ $178.00	High
12/18/2020	Barclays	Boost Target	Overweight	$84.00 ➝ $169.00	Low
12/16/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$100.00 ➝ $150.00	N/A
12/15/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$90.00 ➝ $150.00	High
12/11/2020	The Goldman Sachs Group	Reiterated Rating	Buy	$139.00	Medium
12/9/2020	Needham & Company LLC	Downgrade	Buy ➝ Hold		High
12/3/2020	Bank of America	Boost Target		$105.00 ➝ $150.00	High
12/1/2020	Argus	Boost Target	Hold ➝ Buy	$88.00 ➝ $200.00	High
11/30/2020	Wells Fargo & Company	Boost Target	Equal Weight	$92.00 ➝ $129.00	High
11/25/2020	The Goldman Sachs Group	Boost Target		$107.00 ➝ $139.00	High
11/24/2020	SVB Leerink	Boost Target	Underperform	$59.00 ➝ $60.00	Low
11/23/2020	Wells Fargo & Company	Initiated Coverage	Equal Weight	$92.00	Low
11/17/2020	Redburn Partners	Initiated Coverage	Sell		Medium
11/17/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$109.00	Medium
11/16/2020	Chardan Capital	Boost Target	Positive ➝ Buy	$93.00 ➝ $107.00	High
11/16/2020	Oppenheimer	Boost Target	Outperform	$108.00 ➝ $157.00	High
11/16/2020	Piper Sandler	Boost Target	Overweight	$136.00 ➝ $166.00	High
11/11/2020	Argus	Boost Target	Buy	$80.00 ➝ $88.00	High
11/11/2020	Morgan Stanley	Boost Target	Overweight	$90.00 ➝ $100.00	High
10/8/2020	Chardan Capital	Lower Target	Buy	$95.00 ➝ $93.00	Low
9/24/2020	SVB Leerink	Reiterated Rating	Sell	$41.00	High
9/8/2020	SVB Leerink	Downgrade	Market Perform ➝ Underperform	$58.00 ➝ $41.00	High
8/12/2020	Jefferies Financial Group	Reiterated Rating	Buy	$90.00	Medium
8/12/2020	Oppenheimer	Reiterated Rating	Buy	$108.00	Medium
8/12/2020	SVB Leerink	Lower Target	Market Perform	$60.00 ➝ $58.00	High
8/12/2020	Chardan Capital	Reiterated Rating	Buy	$95.00	High
8/6/2020	Chardan Capital	Reiterated Rating	Buy	$95.00	Low
8/6/2020	SVB Leerink	Lower Target	Market Perform	$65.00 ➝ $60.00	Medium
8/6/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		Medium
8/5/2020	Needham & Company LLC	Initiated Coverage	Buy	$94.00	Medium
7/27/2020	Chardan Capital	Reiterated Rating	Buy	$95.00	High
7/27/2020	SunTrust Banks	Initiated Coverage	Buy	$120.00	High
7/27/2020	The Goldman Sachs Group	Set Target	Buy	$105.00	Medium
7/27/2020	BMO Capital Markets	Boost Target	Outperform	$94.00 ➝ $112.00	Low
7/24/2020	Oppenheimer	Initiated Coverage	Buy	$108.00	High
7/23/2020	SVB Leerink	Initiated Coverage	Market Perform	$65.00	High
7/20/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$60.00 ➝ $89.00	High
7/15/2020	Needham & Company LLC	Initiated Coverage	Buy	$94.00	N/A
7/15/2020	Oppenheimer	Initiated Coverage	Buy	$108.00	N/A
7/15/2020	Piper Sandler	Boost Target		$100.00 ➝ $134.00	High
7/15/2020	Chardan Capital	Boost Target	Buy	$84.00 ➝ $95.00	N/A
7/13/2020	Brookline Capital Management	Reiterated Rating	Buy	$95.00	High
7/13/2020	Jefferies Financial Group	Initiated Coverage	Buy	$90.00	N/A
6/30/2020	Argus	Initiated Coverage	Buy	$80.00	N/A
6/25/2020	Chardan Capital	Reiterated Rating	Buy	$84.00	N/A
6/12/2020	Chardan Capital	Reiterated Rating	Buy	$84.00	N/A
6/11/2020	Needham & Company LLC	Reiterated Rating	Buy	$94.00	N/A
6/8/2020	Barclays	Initiated Coverage	Overweight	$68.00	N/A
6/3/2020	Bank of America	Lower Target		$80.00 ➝ $75.00	Medium
6/2/2020	Oppenheimer	Reiterated Rating	Buy	$108.00	N/A
5/30/2020	Chardan Capital	Reiterated Rating	Buy	$52.00	N/A
5/20/2020	Morgan Stanley	Boost Target	Overweight	$37.00 ➝ $90.00	High
5/19/2020	Bank of America	Boost Target	Neutral	$70.00 ➝ $95.00	N/A
5/19/2020	BMO Capital Markets	Boost Target	Outperform	$83.00 ➝ $112.00	N/A
5/18/2020	Needham & Company LLC	Initiated Coverage	Buy	$94.00	N/A
5/18/2020	Oppenheimer	Boost Target	Outperform	$62.00 ➝ $108.00	N/A
5/18/2020	Piper Sandler	Boost Target	Overweight	$57.00 ➝ $102.00	N/A
5/18/2020	The Goldman Sachs Group	Boost Target	Buy	$63.00 ➝ $105.00	N/A
5/12/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$60.00	N/A
5/11/2020	Roth Capital	Boost Target	Buy	$41.00 ➝ $68.00	N/A
5/8/2020	Oppenheimer	Boost Target	Outperform	$43.00 ➝ $62.00	N/A
5/7/2020	Needham & Company LLC	Boost Target	Buy	$35.00 ➝ $58.00	N/A
5/1/2020	Piper Sandler	Reiterated Rating	Buy	$57.00	N/A
4/30/2020	BMO Capital Markets	Initiated Coverage	Outperform	$83.00	Medium
4/29/2020	BMO Capital Markets	Initiated Coverage	Outperform		N/A
4/28/2020	Chardan Capital	Boost Target	Buy	$40.00 ➝ $52.00	N/A
4/21/2020	Oppenheimer	Initiated Coverage	Buy	$43.00	N/A
4/17/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A
4/17/2020	Piper Sandler	Boost Target		$34.00 ➝ $57.00	High
4/16/2020	Roth Capital	Boost Target		$33.00 ➝ $41.00	High
4/15/2020	Morgan Stanley	Boost Target	Overweight	$30.00 ➝ $37.00	High
4/15/2020	Chardan Capital	Reiterated Rating	Buy	$40.00	N/A
4/15/2020	Oppenheimer	Boost Target	Outperform	$31.00 ➝ $43.00	N/A
4/14/2020	Piper Sandler	Reiterated Rating	Buy		N/A
3/30/2020	Piper Sandler	Reiterated Rating	Buy	$34.00	N/A
3/24/2020	Needham & Company LLC	Reiterated Rating	Buy	$35.00	N/A
3/16/2020	Piper Sandler	Reiterated Rating	Buy	$32.00	N/A
3/16/2020	Chardan Capital	Reiterated Rating	Buy	$40.00	N/A
3/5/2020	Chardan Capital	Reiterated Rating	Buy	$40.00	N/A
3/5/2020	Bank of America	Downgrade	Buy ➝ Neutral	$32.00	N/A
2/27/2020	Roth Capital	Boost Target		$24.00 ➝ $33.00	High
2/26/2020	Needham & Company LLC	Boost Target	Buy	$28.00 ➝ $35.00	High
2/25/2020	Piper Sandler	Reiterated Rating	Buy	$32.00	N/A
2/25/2020	Chardan Capital	Reiterated Rating	Buy	$40.00	N/A
2/11/2020	Chardan Capital	Reiterated Rating	Buy	$40.00	N/A
1/22/2020	Piper Sandler	Reiterated Rating	Buy	$32.00	N/A
1/14/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A
1/10/2020	Chardan Capital	Reiterated Rating	Buy	$40.00	N/A
1/2/2020	Oppenheimer	Downgrade	Outperform	$27.00	Medium
1/2/2020	Morgan Stanley	Initiated Coverage	Overweight	$29.00	N/A
1/2/2020	Barclays	Initiated Coverage	Overweight	$20.00	N/A
1/2/2020	Bank of America	Initiated Coverage	Buy	$20.00	N/A
1/2/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$22.00	N/A
1/2/2020	Needham & Company LLC	Initiated Coverage	Buy	$28.00	N/A
1/2/2020	The Goldman Sachs Group	Initiated Coverage	Buy	$25.00	N/A
1/2/2020	Piper Sandler Companies	Initiated Coverage	Overweight	$24.00	N/A
12/3/2019	Bank of America	Reiterated Rating	Buy	$29.00	High
12/3/2019	Bank of America	Initiated Coverage	Buy	$29.00	N/A
11/6/2019	Needham & Company LLC	Reiterated Rating	Buy	$28.00	N/A
10/25/2019	Roth Capital	Reiterated Rating	Buy		Low
10/25/2019	Roth Capital	Initiated Coverage	Buy	$24.00	N/A
9/15/2019	Chardan Capital	Reiterated Rating	Buy		Low
9/15/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A
9/13/2019	Needham & Company LLC	Set Target	Buy	$28.00	N/A
9/13/2019	Chardan Capital	Set Target	Buy	$40.00	N/A
9/13/2019	Piper Sandler Companies	Reiterated Rating	Buy	$30.00 ➝ $32.00	N/A
8/16/2019	Piper Sandler Companies	Set Target	Buy	$30.00	N/A
8/12/2019	Needham & Company LLC	Reiterated Rating	Buy	$28.00	Medium
8/11/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$24.00	Medium
8/9/2019	Morgan Stanley	Set Target	Buy	$30.00	N/A
6/2/2019	Chardan Capital	Reiterated Rating	Buy	$40.00	High
5/29/2019	Oppenheimer	Boost Target	Outperform	$27.00 ➝ $31.00	N/A
5/8/2019	Piper Sandler Companies	Boost Target	Overweight	$24.00 ➝ $30.00	High

(Data available from 4/25/2019 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

26 very positive mentions
49 positive mentions
12 negative mentions
3 very negative mentions

Mentions as of

9/28/2023

39 very positive mentions
34 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

10/28/2023

6 very positive mentions
29 positive mentions
7 negative mentions
2 very negative mentions

Mentions as of

11/27/2023

23 very positive mentions
36 positive mentions
11 negative mentions
8 very negative mentions

Mentions as of

12/27/2023

29 very positive mentions
56 positive mentions
7 negative mentions
1 very negative mentions

Mentions as of

1/26/2024

43 very positive mentions
40 positive mentions
9 negative mentions
7 very negative mentions

Mentions as of

2/25/2024

41 very positive mentions
35 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

3/26/2024

44 very positive mentions
50 positive mentions
18 negative mentions
3 very negative mentions

Mentions as of

4/25/2024

Current Sentiment

Recent Stories by Sentiment

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $106.18

$103.52

$108.17

50 Day Range

MA: $101.85

$86.99

$111.98

52 Week Range

Now: $106.18

$62.55

$142.79

Volume

2,795,353 shs

Average Volume

4,100,601 shs

Market Capitalization

$40.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Moderna?: The following Wall Street analysts have issued stock ratings on Moderna in the last twelve months: 51job, Inc., Argus, Bank of America Co., Canaccord Genuity Group Inc., Deutsche Bank Aktiengesellschaft, Guggenheim, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, TD Cowen, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and William Blair.
View the latest analyst ratings for MRNA.
What is the current price target for Moderna?: 15 Wall Street analysts have set twelve-month price targets for Moderna in the last year. Their average twelve-month price target is $126.49, suggesting a possible upside of 19.6%. The Goldman Sachs Group, Inc. has the highest price target set, predicting MRNA will reach $231.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $60.00 for Moderna in the next year.
View the latest price targets for MRNA.
What is the current consensus analyst rating for Moderna?: Moderna currently has 2 sell ratings, 8 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MRNA, but not buy more shares or sell existing shares.
View the latest ratings for MRNA.
What other companies compete with Moderna?: Other companies that are similar to Moderna include Seagen, Biogen, argenx, BioNTech and Neurocrine Biosciences. Learn More about companies similar to Moderna.
How do I contact Moderna's investor relations team?: Moderna's physical mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 714-6500 and its investor relations email address is [email protected]. The official website for Moderna is www.modernatx.com. Learn More about contacing Moderna investor relations.

Moderna - MRNA Stock Price Target and Predictions

Analyst Price Target for MRNA

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.49 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Moderna?

What is the current price target for Moderna?

What is the current consensus analyst rating for Moderna?

What other companies compete with Moderna?

How do I contact Moderna's investor relations team?